Ident. | Authors (with country if any) | Title |
---|
000018 |
YIMING XIAO [Canada] ; Pierre Jannin [France] ; Tiziano D'Albis [France] ; Nicolas Guizard [Canada] ; Claire Haegelen [France] ; Florent Lalys [France] ; Marc Verin [France] ; D. Louis Collins [Canada] | Investigation of Morphometric Variability of Subthalamic Nucleus, Red Nucleus, and Substantia Nigra in Advanced Parkinson's Disease Patients Using Automatic Segmentation and PCA-Based Analysis |
000050 |
Mahan Alavi [Canada] ; Jonathan O. Dostrovsky [Canada] ; Mojgan Hodaie [Canada] ; Andres M. Lozano [Canada] ; William D. Hutchison [Canada] | Spatial extent of beta oscillatory activity in and between the subthalamic nucleus and substantia nigra pars reticulata of Parkinson's disease patients |
000054 |
Raymond T. Bartus [États-Unis] ; Tiffany L. Baumann [États-Unis] ; Joao Siffert [États-Unis] ; Christopher D. Herzog [États-Unis] ; Ron Alterman [États-Unis] ; Nicholas Boulis [États-Unis] ; Dennis A. Turner [États-Unis] ; Mark Stacy [États-Unis] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; C. Warren Olanow [États-Unis] | Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients |
000083 |
Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis] | Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat |
000143 |
Aron S. Buchman [États-Unis] ; Sukriti Nag [États-Unis] ; Joshua M. Shulman [États-Unis] ; Andrew S. P. Lim [Canada] ; Veronique G. J. M. Vanderhorst [États-Unis] ; Sue E. Leurgans [États-Unis] ; Julie A. Schneider [États-Unis] ; David A. Bennett [États-Unis] | Locus Coeruleus Neuron Density and Parkinsonism in Older Adults Without Parkinson's Disease |
000277 |
Tyler M. Rolheiser [Canada] ; Heather G. Fulton [Canada] ; Kimberley P. Good [Canada] ; John D. Fisk [Canada] ; J. Roger Mckelvey [Canada] ; Christophe Scherfler [Autriche] ; Naeem M. Khan [Canada] ; Ronald A. Leslie [Canada] ; Harold A. Robertson [Canada] | Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease |
000307 |
Martin Parent [Canada] ; André Parent [Canada] | Substantia Nigra and Parkinson's Disease: A Brief History of Their Long and Intimate Relationship |
000347 |
Myriam Lafreniere-Roula [Canada] ; Elaine Kim [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] ; Mojgan Hodaie [Canada] ; Jonathan O. Dostrovsky [Canada] | High-frequency microstimulation in human globus pallidus and substantia nigra |
000446 |
I. A. Prescott [Canada] ; J. O. Dostrovsky [Canada] ; E. Moro [Canada] ; M. Hodaie [Canada] ; A. M. Lozano [Canada] ; W. D. Hutchison [Canada] | Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients |
000453 |
Emily N. Mangano [Canada] ; Shawn Hayley [Canada] | Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration |
000530 |
Y.-Y. Lai [États-Unis] ; K.-C. Hsieh [États-Unis] ; D. Nguyen [États-Unis] ; J. Peever [Canada] ; J. M. Siegel [États-Unis] | NEUROTOXIC LESIONS AT THE VENTRAL MESOPONTINE JUNCTION CHANGE SLEEP TIME AND MUSCLE ACTIVITY DURING SLEEP : AN ANIMAL MODEL OF MOTOR DISORDERS IN SLEEP |
000590 |
Matthew J. Lavoie [États-Unis] ; Giuseppe P. Cortese [États-Unis] ; Beth L. Ostaszewski [États-Unis] ; Michael G. Schlossmacher [Canada] | The effects of oxidative stress on parkin and other E3 ligases |
000594 |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
000595 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
000596 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
000623 |
Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Lennard P. Niles [Canada] | Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease |
000660 |
L. Borgal [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro |
000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
000694 |
Pepijn Van Den Munckhof [Canada] ; Francois Gilbert [Canada] ; Michel Chamberland [Canada] ; Daniel Levesque [Canada] ; Jacques Drouin [Canada] | Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of parkinson's disease |
000784 |
Sarah A. Baker [États-Unis] ; Lianne E. Stanford [Canada] ; Richard E. Brown [Canada] ; Theo Hagg [États-Unis] | Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice |
000815 |
Deniz Kirik [Suède] ; Anders Björklund [Suède] ; Ivar Mendez [Canada] ; Rosario Sanchez-Pernaute [États-Unis] ; Oliver Cooper [États-Unis] ; Angel Vinuela [États-Unis] ; Daniela Ferrari [États-Unis] ; Lars Björklund [États-Unis] ; Alain Dagher [Canada] ; Ole Isacson [États-Unis] | Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary |
000835 |
Sandrine Thuret [Allemagne] ; Kambiz N. Alavian [Allemagne] ; Martin Gassmann [Suisse] ; C. Kent Lloyd [États-Unis] ; Simone M. Smits [Pays-Bas] ; Marten P. Smidt [Pays-Bas] ; Rüdiger Klein [Allemagne] ; Richard H. Dyck [Canada] ; Horst H. Simon [Allemagne] | The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta |
000935 |
Paul S. Fitzmaurice [Canada] ; LEE ANG [Canada] ; Mark Guttman [Canada] ; Ali H. Rajput [Canada] ; Yoshiaki Furukawa [Canada] ; Stephen J. Kish [Canada] | Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease |
000938 |
Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada] | Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease |
000950 |
LI LIU [Canada] ; Shu S. Hsu [Canada] ; Suneil K. Kalia [Canada] ; Andres M. Lozano [Canada] | Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP |
000993 |
Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
000B11 |
B. M. Ross [Canada] ; N. Mamalias [Canada] ; A. Moszczynska [Canada] ; A. H. Rajput [Canada] ; S. J. Kish [Canada] | Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease |
000B56 |
I. Mendez [Canada] ; K. A. Baker [Canada] ; M. Hong [Canada] | Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease |
000B79 |
X. Lu [Canada] ; G. Bing [États-Unis] ; T. Hagg [Canada] | Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats |
000B86 |
K. A. Baker [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease |
000C48 |
R. A. Hauser [États-Unis] ; T. B. Freeman [États-Unis] ; B. J. Snow [Canada] ; M. Nauert [États-Unis] ; L. Gauger [États-Unis] ; J. H. Kordower [États-Unis] ; C. W. Olanow [États-Unis] | Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease |
000C52 |
A. Richter [Allemagne] ; U. Ebert [Allemagne] ; J. N. Nobrega [Canada] ; J. J. Vallbacka [Canada] ; M. Fedrowitz [Allemagne] ; W. Löscher [Allemagne] | Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior |
000C57 |
G. Flores [Mexique, Canada] ; J. J. Liang [Mexique, Canada] ; A. Sierra [Mexique] ; D. Martinez-Fong [Mexique] ; R. Quirion [Mexique, Canada] ; J. Aceves [Mexique] ; L. K. Srivastava [Mexique] | Expression of dopamine receptors in the subthalamic nucleus of the rat : Characterization using reverse transcriptase-polymerase chain reaction and autoradiography |
000C66 |
D. Frankel [Canada] ; H. M. Schipper [Canada] | Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury |
000D01 |
B. M. Ross [Canada] ; A. Moszczynska [Canada] ; J. Erlich [Canada] ; S. J. Kish [Canada] | Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra : Possible implications for Parkinson's disease |
000D06 |
W. W. Martin [Canada] ; T. E. Roberts [Canada] ; F. Q. Ye [Canada] ; P. S. Allen [Canada] | Increased basal ganglia iron in striatonigral degeneration : In vivo estimation with magnetic resonance |
000D26 |
H. M. Schipper [Canada] ; R. Vininsky [Canada] ; R. Brull [Canada] ; L. Small [Canada] ; J. R. Brawer [Canada] | Astrocyte mitochondria : A substrate for iron deposition in the aging rat substantia nigra |
000D49 |
F. J. G. Vingerhoets [Canada] ; M. Schulzer [Canada] ; D. B. Calne [Canada] ; B. J. Snow [Canada] | Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? |
000D58 |
I. Mendez [Canada] ; M. Hong [Canada] | Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase |
000D78 |
N. A. Tatton [Canada] ; S. J. Kish [Canada] | In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and Acridine Orange Staining |
000E02 |
D. D. Newman [Canada] ; N. Rajakumar ; B. A. Flumerfelt ; A. J. Stoessl [Canada] | A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease |
000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
001051 |
B. J. Snow ; R. F. Peppard ; M. Guttman ; J. Okada ; W. Martin ; J. Steele ; A. Eisen ; G. Carr ; B. Schoenberg ; D. Calne | Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in lytico-bodig : the amyotrophic lateral sclerosis-Parkinsonism-dementia complex of guam |
001089 |
A. H. Rajput ; R. J. Uitti ; S. Sudhakar ; B. Rozdilsky | Parkinsonism and neurofibrillary tangle pathology in pigmented nuclei |
001139 |
A. A. F. Sima ; G. Hoag ; B. Rozdilsky | Shy-Drager syndrome: the transitional variant |
001146 |
A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
001161 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets |
001182 |
M. Takada ; T. Hattori | Collateral projections from the substantia nigra to the cingulate cortex and striatum in the rat |